



TELECOPY/FACSIMILE TRANSMISSION

DATE: April 6, 1998  
PAGES, INCLUDING COVER SHEET: 4  
FROM: PATRICIA A. DUFFY  
EXAMINER, ART UNIT1645  
FAX NUMBER: (703) 305-7939  
PHONE NUMBER: (703) 305-7555

TO: ~~Timothy Torchia, Ph.D.~~ *Ginger Dreger*  
FIRM: GENENTECH, INC.  
ATTORNEY'S DOCKET # OR SERIAL: 08/635,130  
FAX/TELECOPIER NUMBER: 650-952-9881

COMMENTS:

Pursuant to our discussion, enclosed is the proposed examiners amendment, to place the claims in condition for allowance.

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE EXAMINER AT THE TELEPHONE NUMBER LISTED ABOVE.

ALL FAX MACHINES RECEIVE TRANSMISSIONS 24 HOURS PER DAY, SEVEN DAYS PER WEEK.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE EXAMINER LISTED HEREON IMMEDIATELY.

April 6, 1998

Dear Ms. Dreger,

Enclosed is a proposed examiners amendment for your review in application SN 08/635,130. These amendments would place the claims in condition for allowance, pending an interference search.

Sincerely,

*Patricia A. Duffy*  
Exr. Patricia A. Duffy

***In the claims:***

Claim 3. (Twice amended) An isolated nucleic acid, comprising:  
a nucleotide sequence encoding the amino acid sequence for mature AL-2l of [in] SEQ ID NO:2,  
a nucleotide sequence encoding the amino acid sequence for mature AL-2s of [in] SEQ ID NO:4, or  
a nucleotide sequence encoding the extracellular domain of AL-2 as set forth by amino acids 27-219 of [in] SEQ ID NO:2.

Claim 7. (Twice amended) The isolated nucleic acid of claim 3, wherein the AL-2 extracellular domain as set forth by amino acids 27-219 of SEQ ID NO:2 is [joined] fused to an immunoglobulin amino acid sequence.

Canceled claim 8.

Claim 13. (Twice amended) The expression vector of claim 12, wherein the nucleic acid comprises:  
a nucleic acid of SEQ ID NO:1 that encodes mature AL-2l,  
a nucleic acid sequence of SEQ ID NO:3 that encodes mature AL-2s, or  
a nucleic acid sequence of nucleotides 322-900 of SEQ ID NO:1 that encodes AL-2 extracellular domain.

Claim 15. (Twice amended). The host cell of claim 14, wherein the vector comprises:  
a nucleic acid of SEQ ID NO:1 that encodes mature AL-2l,  
a nucleic acid sequence of SEQ ID NO:3 that encodes mature AL-2s, or  
a nucleic acid sequence of nucleotides 322-900 of SEQ ID NO:1 that encodes AL-2 extracellular domain.

Claim 17. (Twice amended) A process which comprises transforming a host cell with an expression vector of claim 12 capable, in the host cell transformed with the vector, of expression the nucleotide sequence that encodes a polypeptide comprising the amino acid sequence for mature AL-2l, mature AL-2s or AL-2 extracellular domain, and culturing the transformed host cells under conditions such that the AL-2 polypeptide is synthesized.

Claim 40. (Once amended) The isolated nucleic acid of claim 3, comprising:  
a nucleic acid sequence of SEQ ID NO:1 that encodes mature AL-2l,  
a nucleic acid sequence of SEQ ID NO:3 that encodes mature AL-2s, or  
a nucleic acid sequence of nucleotides 322-900 of SEQ ID NO:1 that encodes AL-2 extracellular domain.

Added the following new claims.

--Claim 41. The isolated nucleic acid of claim 3, wherein the AL-2l amino acid sequence is fused to an immunoglobulin amino acid sequence.

Claim 42. The isolated nucleic acid of claim 3, wherein the AL-2s amino acid sequence is fused to an immunoglobulin amino acid sequence.--